Optimi Health Appoints Dr Michael Blough to Head Clinical Development

10:54 AM EDT, 09/22/2026 (MT Newswires) -- Optimi Health (OPTI.CN) has appointed Dr Michael Blough as its chief clinical development officer, the company said on Tuesday. Blough is a medical researcher with over 20 years experience. He has worked with Optimi on clinical trial applications since 2022, and will oversee the Phase 2 clinical trial evaluating naturally derived psilocybin-assisted psychotherapy to treat patients with major depressive disorder and the Phase 3 clinical trial evaluating MDMA-assisted psychotherapy for the treatment of PTSD. Optimi Health shares were last seen up CA$0.19, to CA$7.00 on the Canadian Securities Exchange. Price: 7.00, Change: +0.19, Percent Change: +2.79